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Abstract
Introduction: This study estimated the U.S. lifetime per-victim cost and economic burden of 
intimate partner violence.
Methods: Data from previous studies were combined with 2012 U.S. National Intimate Partner 
and Sexual Violence Survey data in a mathematical model. Intimate partner violence was defined 
as contact sexual violence, physical violence, or stalking victimization with related impact (e.g., 
missed work days). Costs included attributable impaired health, lost productivity, and criminal 
justice costs from the societal perspective. Mean age at first victimization was assessed as 25 
years. Future costs were discounted by 3%. The main outcome measures were the mean per-victim 
(female and male) and total population (or economic burden) lifetime cost of intimate partner 
violence. Secondary outcome measures were marginal outcome probabilities among victims (e.g., 
anxiety disorder) and associated costs. Analysis was conducted in 2017.
Results: The estimated intimate partner violence lifetime cost was $103,767 per female victim 
and $23,414 per male victim, or a population economic burden of nearly $3.6 trillion (2014 US$) 
over victims’ lifetimes, based on 43 million U.S. adults with victimization history. This estimate 
included $2.1 trillion (59% of total) in medical costs, $1.3 trillion (37%) in lost productivity 
among victims and perpetrators, $73 billion (2%) in criminal justice activities, and $62 billion 
(2%) in other costs, including victim property loss or damage. Government sources pay an 
estimated $1.3 trillion (37%) of the lifetime economic burden.
Conclusions: Preventing intimate partner violence is possible and could avoid substantial costs. 
These findings can inform the potential benefit of prioritizing prevention, as well as evaluation of 
implemented prevention strategies.
Address correspondence to: Cora Peterson, PhD, National Center for Injury Prevention and Control, Centers for Disease Control and 
Prevention, Mailstop F-62, 4770 Buford Highway, Atlanta GA 30341. cora.peterson@cdc.hhs.gov. 
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INTRODUCTION
In 2012, an estimated 26% of U. S. women and 10% of men reported their lives had been 
impacted (e.g., missed work or post-traumatic stress disorder [PTSD] symptoms) by contact 
sexual violence, physical violence, or stalking by an intimate partner.1 Even more adults 
reported other forms of intimate partner violence (IPV), including noncontact sexual 
violence and psychological aggression.1 IPV victimization is associated with poor short- and 
long-term physical and mental health outcomes.2–4
Few studies have quantified the IPV per-victim cost, which at a minimum includes victims’ 
impaired health, lost productivity, and criminal justice costs,5,6 and no study has addressed 
victims’ long-term health costs. A 1995 National Violence Against Women analysis 
estimated the cost of IPV limited to acute and short-term follow-up medical costs and 
included only female victims ($838 per rape, $816 per physical assault, and $294 per 
stalking victimization [1995 US$]6; or, $1,210, $1,178, and $424 as 2014 US$7). Following 
the methodology and presentation of a recent study that estimated the per-person lifetime 
cost of rape,8 this study aims to combine previous studies’ data with current administrative 




Mathematical model inputs included: number of U.S. adults (aged ≥ 18 years) with any 
lifetime and past 12 months IPV exposure, selected attributable, or marginal, health and 
other outcomes associated with IPV from administrative data and previous studies, and the 
marginal cost of those outcomes. Marginal outcome refers to the proportion of victims with 
an outcome beyond the proportion among nonvictims, and is used to calculate the 
attributable cost of IPV.
The main outcome measures were: (1) lifetime IPV cost per victim, and (2) lifetime IPV 
cost in the U.S. population (or economic burden) of currently non-institutionalized adults 
(hereafter, U.S. population), calculated as the lifetime cost per victim multiplied by the 
estimated victim population. Medical, lost productivity, and criminal justice costs were 
included. This analysis used the societal cost perspective (i.e., all payers), a lifetime time 
horizon, and assumed first IPV victimization occurred at victim average age of 25 years.9 
Future costs were discounted by 3%.10 Costs are presented as 2014 US$ unless otherwise 
noted, inflated using selected indices.7,11 Analysis was conducted in 2017 using publicly 
available data.
Measures
The economic burden is based on the 2012U. S. National Intimate Partnerand Sexual 
Violence Survey (NISVS) estimated number of males and females with lifetime IPV 
exposure, defined as contact sexual violence, physical violence, or stalking by an intimate 
partner and related impact1 (Table 1, Appendix Tables 1–5, available online, report expanded 
data and calculations). Contact sexual violence included rape, being made to penetrate, 
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sexual coercion, and unwanted sexual contact. Physical violence included being slapped, 
pushed, hit, kicked, hurt by pullinghair, slammed against something, attempting to hurt by 
choking or suffocating, beaten, burned on purpose, or a perpetrator using a knife or gun. 
Stalking included repeated harassing or threatening behaviors (e.g., watch-ing, following, 
orcontacting), causing the victim to be very fearful or concerned for safety; IPV-related 
impacts included being fear-ful; concerned for safety; PTSD symptoms; injury; needing 
medi-calcare; contracting sexually transmitted infection (STI); becoming pregnant; need for 
housing, advocate, or legal services; missing ≥1 day of work or school; or contactingacris is 
hotline.
IPV outcomes, identified through a targeted literature search, were included based on 
reference studies’ U.S. population representativeness and study design (Appendix Table 3, 
available online). Studies addressing female and male victims were priori-tized. Reported 
outcomes had to facilitate calculation of victims’ marginal probability of the outcome; for 
example, outcome prevalence among non-victims and an AOR of the relationship between 
the outcome and respondents’ IPV exposure, controlling for relevant factors.44 Studies that 
aligned with this study’s exposure definition were prioritized. Unit costs represented the 
attributable cost of analyzed outcomes based on direct comparison of affected and 
unaffected individuals (Appendix Table 4, available online). Comprehensive lifetime unit 
costs that included medical care and lost work productivity and controlled for related 
conditions (e.g., depression and anxiety) were prioritized. Some lifetime costs were 
estimated from annual costs by multiplying the annual cost over the age range of 
respondents in the cost reference study, bounded by this study’s average age at first 
victimization (25 years)9 and current population life expectancy (79 years45; Appendix 
Table 5, available online). Prevention costs were excluded whenever possible.
A previous NISVS analysis limited to short-term lost productivity costs reported that female 
and male victims of IPV, sexual violence, or stalking each lost days from school and work 
valued at $1,063 (females) and $357 (males) (Table 1).9 Average annual data from 2006–
2015 National Crime Victimization Survey indicated 15.3% (n=137,155 survey-weighted) of 
IPV victimizations (rape or sexual assault, robbery, aggravated assault, and simple assault) 
included victim property loss or damage, valued at a mean $1,181 per victimization (applied 
in this study as per-victim cost, which is an underestimate for victims with multiple 
victimizations; Table 1; unpublished data, U.S. Department of Justice). Among IPV 
victimizations (n=745,946 female and n=151,910 male, surveyed-weighted) from annual 
average 2006–2015 National Crime Victimization Survey data, 1.9% of female and 0% of 
male victimizations required treatment for nonfatal injuries in a doctor’s office, 6.6% of 
females and 4.6% of males required treatment in an emergency department, and 0.2% of 
females and 0.1% of males were admitted as inpatients (all applied as per-victim estimates 
in this study; Table 1; unpublished data, U.S. Department of Justice). Unit costs were the 
estimated payment for a doctor’s visit12 and the lifetime medical and lost productivity costs 
for an emergency department visit or admission for physical assault or sexual assault13 
(Table 1). In 2012, there were an estimated 1,256 murders (992 females, 264 males) 
perpetrated by intimate partners (Appendix Table 3, available online).14,15 Unit costs were 
medical care and lost productivity due to homicide.13
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A 2010–2012 NISVS analysis indicated 26.2% of females with lifetime IPV vaginal rape 
exposure had rape-related pregnancy.17 Data from a study of a convenience sample of 
females (n=148) seeking a protection order from an intimate partner reported the outcome of 
IPV rape-related pregnancies (n=32; i. e., 81% live birth, 16% abortion, 3% still born).16 
Unit costs were estimated payments for medical treatment for medically assisted abortion,19 
pregnancy and delivery,18 and stillborn hospital birth20 applied to the estimated number of 
female IPV vaginal rape victims in 2012 NISVS1,1,16,17,46 (i.e., cost of child-rearing not 
included; Table 1).
A nationally representative U.S. study of adult (aged ≥ 18 years) married or common law 
respondents (n=2,254) reported statistically significantly higher prevalence of anxiety 
disorder (including PTSD) among females but not males who reported victimization by a 
current intimate partner.3 A longitudinal study of young adults (n=1,516) assessed the 
impact of incident dating violence and reported a significantly greater prevalence of 
depression among females but not males.22 That study’s results are broadly supported by 
other studies with only female respondents, which did not report data amenable for inclusion 
in this study’s model.47,48 Unit costs were medical and lost productivity costs for anxiety 
disorder (including PTSD)21 and depression23 (Table 1).
Data from 18 states in the 2005 Behavioral Risk Factor Surveillance System survey 
(n=70,156 respondents) indicated significantly higher self-reported prevalence of alcohol 
abuse and smoking, as well as medically diagnosed asthma, coronary heart disease, joint 
disease, and stroke among females and males aged ≥ 18 years with lifetime exposure to 
threatened, attempted, or completed physical violence and nonconsensual sex perpetrated by 
a current or former intimate partner.4 Unit costs were the estimated lost work productivity 
value and medical payments for excess alcohol use,24,25 smoking,29 asthma,30 
cardiovascular disease,37–39 and joint pain36 (Table 1). Another nationally representative 
U.S. study of adults (aged 18 years), indicated higher self-reported prevalence of recent 
cannabis use among females and males recently victimized by an intimate partner,26 
assessed here as the medical and lost productivity cost of illicit drug use.27
A large random sample of females (n=1,928) aged 18 64 years at one U.S. managed care 
plan who reported recent IPV-had significantly higher medically diagnosed prevalence of 
headaches, gastroesophageal reflux, STI, and urinary tract infections34 (Table 1). Unit costs 
were the estimated lost work productivity value and medical payments for moderate pain,36 
gastroesophageal reflux,35 STI,40–42 and urinary tract infections.43 Another large survey of 
females (n=1,152) aged 18 65 years consecutively surveyed at family practice clinics 
indicated-a higher prevalence of blindness or glaucoma among females with current IPV 
compared with females with no IPV exposure.31 Unit costs were the medical32 and lost 
productivity33 cost of blindness and visual impairment.
Similar to a previous study,8 authors used a top-down accounting approach to estimate the 
cost of IPV-related criminal justice activities. Authors’ annual IPV-related criminal justice 
expenditure estimate was $5.7 billion (or $80,632 per convicted IPV perpetrator, both as 
2012 US$; Table 2 and Appendix Table 2, available online; included in the model as 
$83,294 in 2014 US$ [Table 1]).49–60 Department of Justice funding for victims’ services 
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(e.g., transitional housing) at the federal, state, and local levels was included via this method. 
With this approach authors could not identify the per-victim cost of such services, and it was 
not feasible to selectively exclude federal grant money that funds IPV prevention programs61 
or civil court proceedings.62 This approach neither accounts for public criminal justice 
expenditures outside of dedicated budgets,63 nor nonpublic expenditures on related 
activities. Lost productivity because of incarceration was the annual production value of the 
U.S. non-institutional population64 multiplied by authors’ average estimated number of 
years IPV perpetrators are incarcerated (2.3 years) (Table 1, Table 2, Appendix Tables 2, 4, 
and 5, available online).
Statistical Analysis
Authors multiplied the marginal probability of selected outcomes by associated unit costs to 
estimate the per-person lifetime cost of IPV for females and males. The sex-specific, per-
person estimated cost of IPV was multiplied by the estimated number of females and males 
with lifetime IPV exposure to estimate the total U.S. lifetime economic burden of IPV. 
Government costs were assessed as total criminal justice costs plus the estimated 
government share of all medical spending (i.e., 59.8%).65
RESULTS
The present-value, per-victim IPV lifetime cost was $81,960, or $3.6 trillion for all victims, 
based on 32 million U.S. females and 12 million males with any lifetime victimization 
(Table 1). The per-victim cost was $103,767 for females and $23,414 for males, representing 
outcomes differences (e.g., rape-related pregnancy) and differences in the proportion of 
affected victims by sex for particular outcomes (Table 1).
The economic burden estimate included $2.1 trillion (59% of total) in medical costs, $1.3 
trillion (37%) in lost productivity among victims and perpetrators, $73 billion (2%) in 
criminal justice activities, and $62 billion (2%) in other costs, including victim property loss 
or damage. Government sources pay an estimated $1.3 trillion (37%) of the economic 
burden (Table 1).
DISCUSSION
The per-victim lifetime cost ($103,767 for females, $23,414 for males) is the estimated cost 
of IPV exposure. A recent study using NISVS data and similar methods estimated the 
lifetime per-victim cost of rape, including intimate partner perpetrators, to be $122,461 
(2014 US$).8 Other comparative cost estimates include the lifetime per-victim cost of 
nonfatal child maltreatment66 ($210,012 as 2010 US$, or $225,408 as 2014 US$7) and 
smoking29 ($219,889 for males and $106,050 for females as 2000 US$, or $292,010 and 
$139,119 as 2014 US$,7 respectively).
The per-victim estimate could change with new information about victim outcomes or unit 
costs. Barring substantial changes to the per-victim cost, the lifetime economic burden 
estimate ($3.6 trillion) will remain relatively stable, as it is based on the number of U.S. 
adults with lifetime IPV victimization and IPV-related impact; such a large population 
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experiences modest incremental demographic changes. The estimated number of victims 
with IPV exposure in the past 12 months (5,244,000 females and 2,150,000 males1) had a 
lesser effect on the economic burden—only through criminal justice and fatalities costs. The 
economic burden represents costs over adult victims’ lifetimes; therefore, it includes costs 
already experienced among older living adult victims and future costs among younger living 
adult victims. Although it is unknown what proportion of victims in the previous 12 months 
were first-time victimizations, applying this study’s per-victim cost estimate yields an 
approximate annual economic burden of $594 billion. A comparative study estimated the 
annual economic burden of child maltreatment was $124 $585 billion (2010 US$; or $133–
$628 billion as 2014 US$7).66
Limitations
This study used outcome data from observational studies but assumed IPV was the cause of 
victims’ higher observed prevalence of various outcomes; the status of these outcomes as 
risk factors for, correlates with, or outcomes of IPV is complex.48 This means if victims and 
perpetrators experiencing costs related to IPV would have incurred the same costs because 
of other risk factors, then this study has overstated the cost attributable to IPV. Future 
longitudinal analysis of IPV and health outcomes might address this issue, along with issues 
related to timing of IPV exposure and the effects of multiple victimizations. This study did 
not include non-monetary elements, sometimes presented as intangible costs—a monetized 
version of victims’ pain and suffering.67 Costs to victims’ and perpetrators’ friends and 
families were not included. Costs to employers and insurance companies were not measured. 
Government costs were underestimated because reduced tax revenue due to victims’ lost 
work productivity was not included.
The lifetime cost of some outcomes was inferred from annual cost data (Appendix Table 5, 
available online), which is a major limitation; this assumes an accurate distribution of 
patients at all stages of a particular outcome (i.e., acute, recurring, remission) in reference 
studies’ annual estimates and, when applied to individuals, may overstate lifetime medical 
costs. For example, the annual cost of depression and other conditions was uniformly 
applied to affected victims for multiple years. Based on available data, it was not possible to 
assign costs by victim demographics or time since IPV exposure. The depression cost 
estimate referred to major depressive disorder, which represents severe depression. 
Reference cost studies on non-IPV populations were used for unit costs; such populations 
may differ in demographic distribution from the IPV victim population. This study did not 
address the possibility that incarcerating perpetrators could result in fewer IPV victims or 
victimizations.
Health outcomes that could be linked to specific costs were included, though authors did not 
attempt to assign a cost to increased risk factors (e.g., IPV victims have higher prevalence of 
activity limitations and HIV risk factors4,34). The cost of nonfatal suicide attempts was not 
included independent of anxiety and depression costs.48 The model applied a unit cost of 
illicit drugs to the marginal prevalence of cannabis use among IPV victims; state-based 
legalization of non-medical cannabis use (first occurred in late 2012) may decrease the 
applicability of this unit cost for this outcome in future years. This analysis focused on the 
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prevalence and cost of formally defined health conditions as assessed in previous studies, 
such as anxiety (including PTSD) defined by the Composite International Diagnostic 
Interview 2.1.26 How ever, a much higher proportion of IPV victims have reported 
individual symptoms of PTSD (e.g., nightmares, feeling numb or detached1). Several lost 
productivity unit estimates included employed respondents only, and valued respondents’ 
productivity using the human capital approach (i.e., lost wages)—rather than value per 
statistical life approach—which undervalues lost productivity. Several lost productivity 
estimates from previous studies did not include mortality. Long-term lost productivity 
among IPV victims not diagnosed with any of the analyzed outcomes was not included.
Discounting assumed victims’ mean age at first IPV victimization was 25 years, which 
underestimates costs among victims with first victimization at less than 25 years and 
overestimates costs among victims with first victimization at more than 25 years. First 
victimization occurs in adolescence for some IPV victims.1 If first IPV exposure age was 
instead 18 years, the estimated lifetime cost would increase (per victim: female=$104,238, 
male=$24,298; data not shown). At an alternative 7% discount rate, the present value cost 
per victim would be lower (female=$73,378, male=$19,812; data not shown).
Too few reference studies met quality and reporting criteria for a meaningful deterministic 
sensitivity analysis (e.g., range test per outcome), and too few reported measures of 
dispersion for a meaningful probabilistic sensitivity analysis (e.g., distribution test based on 
CIs; Appendix Table 3, available online). Identifiable cost double-counting includes: HIV 
costs appear in both STI and illicit drug use unit costs, and some anxiety and substance use 
costs are included in the depression cost (Appendix Tables 3 and 4, available online). A 
small portion of the illicit drug and excess alcohol unit costs comprised research and 
prevention activities.24,25,27,28 Some reference studies focused on outcomes among adults 
who experienced current or recent IPV or recent outcomes (e.g., STI) rather than lifetime 
assessment (Appendix Table 3, available online). The short-term lost productivity estimate 
included lifetime stalking and sexual violence victimizations by non-intimate partners.9
This study is notably limited by inexact timelines related to intimate partner victimizations 
during victims’ lifetimes, number of victimizations per victim, number of victims per 
perpetrator, onset of attributable health outcomes, and treatment of those outcomes and 
related conditions. This study’s acute cost estimates (e.g., short-term medical care) are per 
victim, rather than per victimization, which underestimates consequences among victims 
with multiple victimizations.68 Owing to available data, this study did not address costs 
among specific subpopulations of IPV victims, including men who have sex with men. This 
study did not include IPV effects on non-rape pregnancies (e.g., higher prevalence of 
preterm birth69) or on children exposed to IPV (e.g., child abuse and neglect70) because 
population prevalence data are lacking.71 Some health outcomes measured to be more 
prevalent among female victims have not been assessed among male victims (e.g., 
blindness).
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CONCLUSIONS
Despite limitations, this study’s estimate of IPV per-victim lifetime cost ($103,767 for 
females, $23,414 for males) included more comprehensive information on victims’ lifetime 
mental and physical health compared with previous estimates and provides IPV cost 
estimates by impact category. Findings on the cost of IPV can support the need for 
prevention programs and inform intervention evaluations, identifying cost-effective 
approaches to eliminate IPV and its substantial impact on public health and public safety. 
The Centers for Disease Control and Prevention’s technical packages help communities use 
the best available evidence on strategies to stop sexual partner violence and IPV before it 
starts, including prevention efforts among adolescents and young adults, and support 
survivors to lessen harms.72,73
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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